Pharnext Announces PXT3003 was Granted Priority Review by the China Food and Drug Administration
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomic data and artificial intelligence, today announced that PXT3003 was granted priority review for Charcot-Marie-Tooth Type 1A disease (CMT1A) by the China Food and Drug Administration (CFDA).
Pharnext’s first-in-class PLEODRUG™ PXT3003 is currently in a Phase 3 clinical trial in Europe and the United States, with results expected before the end of 2018. PXT3003, developed using Pharnext’s R&D platform PLEOTHERAPY™, is a novel oral fixed-low dose combination of baclofen, naltrexone and sorbitol, with EMA and U.S. FDA Orphan Drug Designation.
GeneNet Co, Ltd, a joint venture between Tasly and Pharnext, owns the commercialization rights for PXT3003 for CMT1A in Greater China (Mainland China, Hong Kong, Taiwan, and Macau), as well as exclusive license rights to all PXT3003 patents applied for and authorized in Greater China.
In December 2017, GeneNet applied for clinical approval for PXT3003 to be registered as an imported pharmaceutical in China. PXT3003’s inclusion in the priority review process will greatly shorten the waiting time for clinical approval and also expedite registration as an imported pharmaceutical.
“We are pleased that PXT3003 has been identified as a priority by the CFDA, and that its fast-track status will decrease the waiting time for the drug’s approval,” said Prof. Daniel Cohen, M.D., Ph.D., Pharnext’s Co-Founder and CEO.
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth Type 1A disease and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big data genomics and artificial intelligence: PLEOTHERAPY™. The Company identifies and develops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics, and is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit www.pharnext.com.
Tasly Pharmaceutical Group Co., Ltd. was listed on the Shanghai Stock Exchange in August 2002 (Stock Code 600535). The company concept is "To share the joy of health with all” and the company mission “To improve human life and quality of life.” Tasly is committed to promoting the integration of Traditional Chinese Medicine (TCM) with modern medical and pharmaceutical technologies. It is also committed to building the first international brand of modernized TCM. “To become the global innovation leader of modern TCM and the scientific standard maker of modern TCM” is our target. To achieve this goal, Tasly will strive to bring modernized TCM to international pharmaceutical standards. To support its development strategy of “Comprehensive Internationalization,” Tasly has set up a complete manufacturing chain which respects international guidelines and exploits intelligent manufacturing systems. Based on its “Two Wheels of Innovation and Capitalization” strategy, Tasly has developed several core competitive advantages, such as its R&D model, a multi-level product system, a multi-dimensional patent protection system and a commercial and marketing network.
René GoedKoop, +33 (0)1 41 09 22 30
Chief Medical Officer
Financial Communication (France)
Stéphane Ruiz, +33 (0)1 56 88 11 15
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1-212-362-1200
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Media Relations (Europe)
Bruno Arabian, +33 (0)1 81 70 96 30
Media Relations (U.S.)
Kate L. Barrette, +1-212-223-0561
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Chubu Centrair International Airport Has Been Ranked 5-Star Airport for Second Time19.11.2018 11:19 | Pressemelding
Chubu Centrair International Airport has been ranked for the second consecutive year as a 5-star Airport*1, the world highest airport rank, in the Regional Airport*2 category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181119005317/en/ In order to reply to the diversifying needs of the increasing international travellers, Chubu Centrair International Airport is aiming to become an easier to use and a more comfortable airport. In SKYTRAX’s*3 survey, which includes over 500 airport evaluation categories, Chubu Centrair International Airport has ranked specially high in “Airport staff service” and ”Airport cleanness” among other airports. In addition, Chubu Centrair International Airport has been also awarded in SKYTRAX’s “World Airport Awards”, an international airport rating based on client service, as “The World’s Best Regional Airport” (for 4th consecutive year since 2015) and ”Best Regional Airport-Asia” (for 8th conse
Blommer Chocolate to Be Acquired by Fuji Oil Holding19.11.2018 09:03 | Pressemelding
The Blommer Chocolate Company, the largest ingredient chocolate manufacturer in North America and third largest in the world, announced that it has entered into an agreement to be acquired by Fuji Oil Holding, Inc., a global leader in oil and fat ingredients serving the food industry. The sale includes all Blommer business entities, including its four manufacturing operations in North America and one in Shanghai. Blommer is a private, family-owned company; Fuji Oil is publicly traded on the Tokyo Stock Exchange. “For nearly 80 years, our family business has grown to become a major ingredients supplier to most of the iconic brands across a wide variety of food categories,” said Peter Blommer, CEO and third-generation family member. “This is a landmark event in the proud history of Blommer Chocolate Company and begins an exciting new chapter as we look forward to joining a highly respected global leader in Fuji Oil. Our companies share common values and a deep commitment to product quali
GSMA Announces New Speakers for Mobile 360 Series – MENA19.11.2018 09:00 | Pressemelding
The GSMA today announced a number of additional high-profile speakers for its Mobile 360 Series – MENA (Middle East and North Africa) conference taking place on the 26-27 November 2018 in Dubai. The mobile industry-focused event, which is now in its sixth year, will cover the key industry issues facing the region, with a particular emphasis on transformative technologies including artificial intelligence (AI), blockchain and 5G. “Mobile is having a transformative impact across this diverse region with mobile operators in the GCC states laying the foundations for leadership in 5G and planning ahead to commercial launches, while the region’s emerging markets are seeing rising smartphone adoption,” said John Giusti, Chief Regulatory Officer, GSMA. “We have a incredible line-up of expert speakers this year, ready to outline the key issues and challenges facing the region – we’re looking forward to a thought-provoking and exciting showcase.” New speakers added to the agenda include: Hakam K
Telefónica Deutschland Selects SIAE MICROELETTRONICA for Turn-Key DCN Migration Services in Germany19.11.2018 08:00 | Pressemelding
Telefónica Deutschland , a leading integrated telecommunications provider in Germany awards SIAE MICROELETTRONICA, a long-term strategic partner for wireless transmission solutions, a turn-key contract for DCN (Data Communication Networks) migration services across its backhaul network. Following the successful acquisition of E-Plus, Telefónica Deutschland new backhaul network counts over 30.000 microwave radio links from three different vendors, including SIAE MICROELETTRONICA. In preparation for a potential 5G launch in the future, Telefónica is taking steps to simplify operations and maximize performances and coherence across its network. With these activities Telefónica plans to update its DCN by implementing a new common-DCN architectural model. The migration services entrusted to SIAE MICROELETTRONICA include project- management, IP network design, new-model implementation and operation service delivery. The cluster-by-cluster migration process consists of a mix of remote configu
Dentons Global Chairman and Global Chief Executive Officer Re-Elected19.11.2018 08:00 | Pressemelding
Dentons, the world's largest law firm, announced today that Joseph Andrew and Elliott Portnoy have been re-elected to three-year terms as Global Chairman and Global Chief Executive Officer, respectively. They have led the firm together since its formation in March 2013. Messrs. Andrew and Portnoy ran without opposition and have been the entrepreneurial drive and architects of Dentons’ client-centric strategy and polycentric approach to law firm management, resulting in a period of unprecedented growth while many law firms are contracting as they are buffeted by the changes shaping the legal profession globally. Under their leadership, Dentons has grown into the world’s largest law firm with more than 9,600 lawyers operating in 174 locations and 78 countries. During this same time, the firm has successfully completed dozens of business combinations throughout markets in Africa, ASEAN, Australia, Canada, Caribbean, China, Europe, Latin America, Middle East, United Kingdom and United Stat
Biosense Webster Launches Report - The Burden of Atrial Fibrillation: Understanding the Impact of the New Millennium Epidemic Across Europe19.11.2018 06:00 | Pressemelding
Biosense Webster EMEA, a Division of Johnson & Johnson Medical NV/SA and leader in the treatment of Atrial Fibrillation (AF) has today, during AF Association Global AF Aware Week, published a report that uncovers the growing burden of AF on patients, caregivers and healthcare systems across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181118005008/en/ The new report is calling for greater awareness and emphasis on the scale and impact of AF which is fast becoming one of the world’s most significant health issues. The new millennium epidemic not only disrupts the quality of life for the 11 million people across Europe who suffer from AF, but also costs healthcare systems up to €3,286 million annually across European countries.2-7 AF is characterized by an irregular and often fast heart rhythm that results in uncoordinated contraction of the top two chambers of the heart. The irregular heart rhythm may cause blood cl